Recruiting PHASE4 INTERVENTIONAL 2-arm NCT04490031

Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Randomized Control Study Evaluating Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Sponsor: Universiti Kebangsaan Malaysia Medical Centre

Updated 6 times since 2020 Last updated: Jul 24, 2020 Started: Mar 1, 2020 Primary completion: Dec 31, 2020 Completion: Apr 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Ketamine Adverse Reaction and is currently actively recruiting participants. Universiti Kebangsaan Malaysia Medical Centre leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE4

Status: Unknown Status → Recruiting
Apr 2022 — Mar 2023 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Apr 2022 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universiti Kebangsaan Malaysia Medical Centre

Data source: Universiti Kebangsaan Malaysia Medical Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bandar Tun Razak, Malaysia